120 completed, 29 recruiting, 28 unknown, 20 active not recruiting. 75 Phase 2, 56 Phase 1, 49 Not applicable, 38 Phase 3, 5 Phase 4.
Follow Multiple Sclerosis, Chronic Progressive: new trials by email Literature Review of Multiple Sclerosis, Chronic Progressive trials Research Report on Multiple Sclerosis, Chronic Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS Remibrutinib (Open Label) - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive | Phase 2 | Not yet recruiting | Moein Amin | 20 | 2027-03-01 | 2026-08-19 |
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy C-CAR168 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | AbelZeta Inc. | 119 | 2027-02-01 | 2026-10-13 |
| A Basket Study of CTA313 in Participants With Active Autoimmune Diseases CTA313 UCAR T Cell Infusion - Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS) | Phase 1 | Not yet recruiting | Imviva Bio | 81 | 2026-12-01 | 2026-08-24 |
| Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care Cohort - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive | Not yet recruiting | Luxembourg Institute of Health | 100 | 2026-12-01 | 2026-09-22 | |
| Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis. Online wellness course and online exercise platform, Usual Care Group - Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS) | Not applicable | Not yet recruiting | University of Iowa | 118 | 2026-11-15 | 2026-09-28 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease CTX112 - Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica | Phase 1 / Phase 2 | Not yet recruiting | CRISPR Therapeutics | 220 | 2026-11-01 | 2026-10-22 |
| A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS) SUN-627, Placebo - Primary Progressive Multiple Sclerosis, Primary Progressive MS | Phase 2 | Recruiting | Sundance Biosciences, Inc. | 20 | 2026-10-01 | 2026-09-25 |
| A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases LVIVO-TaVec400 product - Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD) | Early Phase 1 | Withdrawn | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2026-09-23 | 2026-10-02 | |
| Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis SYS6020 injection - Multiple Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | Tongji Hospital | 25 | 2026-09-16 | 2026-08-10 |
| A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy OCR SC - Multiple Sclerosis | Phase 4 | Recruiting | Genentech, Inc. | 100 | 2026-09-02 | 2026-09-30 |
| Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS) Indapamide - Multiple Sclerosis | Phase 2 | Not yet recruiting | Eva M.M. Strijbis | 75 | 2026-09-01 | 2026-08-14 |
| IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis IDP-023, Ocrelizumab, Interleukin-2 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS) | Phase 1 | Suspended | Indapta Therapeutics, INC. | 34 | 2026-06-30 | 2025-04-30 |
| Acute Intermittent Hypoxia Combined With Gait Training in Multiple Sclerosis Acute Intermittent Hypoxia (AIH), Sham Acute Intermittent Hypoxia (AIH), Myoelectric Interface Neurorehabilitation Training (MINT) - Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting | Not applicable | Not yet recruiting | Shirley Ryan AbilityLab | 35 | 2026-06-15 | 2026-06-08 |
| RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis CABA-201 - Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS) | Phase 1 / Phase 2 | Withdrawn | Cabaletta Bio | 2026-06-01 | 2026-06-25 | |
| Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis S103 cells - Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis | Phase 1 | Recruiting | Xijing Hospital | 9 | 2026-05-08 | 2026-08-05 |
| A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis Orelabrutinib, Placebo - Secondary Progressive Multiple Sclerosis | Phase 3 | Recruiting | Zenas BioPharma (USA), LLC | 990 | 2026-03-23 | 2026-10-21 |
| A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis Orelabrutinib, Placebo - Multiple Sclerosis (MS) Primary Progressive | Phase 3 | Recruiting | Zenas BioPharma (USA), LLC | 705 | 2026-03-23 | 2026-10-20 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) RO7268489, Ocrelizumab, Placebo - Progressive Multiple Sclerosis | Phase 2 | Recruiting | Hoffmann-La Roche | 360 | 2026-03-10 | 2026-10-07 |
| Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis TRX319, Bendamustine - Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS) | Phase 1 / Phase 2 | Recruiting | Tr1X, Inc. | 39 | 2026-03-01 | 2026-09-21 |
| Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis Amniotic fluid or placental CD117 stem cells - Multiple Sclerosis, Progressive | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2026-02-01 | 2026-02-06 |
Showing 20 of 242. Sign in to see all of them.
Multiple Sclerosis (135) · Multiple Sclerosis, Relapsing-Remitting (70) · Autoimmune Diseases (11) · Fatigue (10) · Demyelinating Diseases (8) · Nervous System Diseases (8) · Autoimmune Diseases of the Nervous System (7) · Motor Activity (7) · Depression (4) · Disease Progression (4) · Hypoxia (4) · Nerve Degeneration (4) · Neuromyelitis Optica (4) · Recurrence (4)
Chronic Disease (242) · Disease Attributes (242) · Pathological Conditions, Signs and Symptoms (242) · Demyelinating Autoimmune Diseases, CNS (239) · Immune System Diseases (239) · Pathologic Processes (239) · Autoimmune Diseases of the Nervous System (235) · Demyelinating Diseases (234) · Nervous System Diseases (234) · Autoimmune Diseases (231) · Multiple Sclerosis (107) · Signs and Symptoms (20) · Behavior (11) · Central Nervous System Diseases (8) · Cranial Nerve Diseases (8)
ocrelizumab (17) · Rituximab (9) · siponimod (7) · Methylprednisolone (5) · Sodium Chloride (5) · Interferon beta-1b (4) · Natalizumab (4) · Thioctic Acid (4) · Acetylcysteine (3) · Acyclovir (3) · Blood Specimen Collection (3) · Cladribine (3) · Dimethyl Fumarate (3) · Insemination, Artificial, Homologous (3) · MBP-8298 (3)
Novartis Pharmaceuticals (13) · Hoffmann-La Roche (9) · Copenhagen University Hospital, Rigshospitalet (6) · Biogen (5) · Johns Hopkins University (5) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Shirley Ryan AbilityLab (5) · Bayer (4) · State University of New York at Buffalo (4) · AB Science (3) · Genentech, Inc. (3) · Genzyme, a Sanofi Company (3) · Novartis (3) · Sanofi (3) · University College, London (3)
United States (104) · United Kingdom (33) · France (30) · Germany (30) · Canada (29) · Spain (27) · Italy (25) · Poland (22) · Denmark (19) · Belgium (15) · Czechia (15) · Netherlands (15) · Switzerland (15) · Australia (14) · Hungary (14)
Bibiana Bielekova, M.D. (4) · Audrey Hicks, PhD (2) · Jeremy Chataway (2) · Patrick Vermersch, MD, PhD (2) · Peter Sguigna, MD (2) · Roman Gonzenbach, MD (2) · Scott Newsome, DO (2)
PMID 36163349, PMID 39251561, PMID 40258203, PMID 19847907, PMID 27574516, PMID 28002688, PMID 34376508, PMID 35031587, PMID 35379762, PMID 35945550, PMID 37652990, PMID 42546561, PMID 11405811, PMID 11911515, PMID 12324550, PMID 12525714, PMID 12527959, PMID 12700753, PMID 16015332, PMID 16678208, PMID 19798728, PMID 19847908, PMID 20023002, PMID 20156050, PMID 20404843, PMID 20621711, PMID 21056491, PMID 21187202, PMID 21261965, PMID 22691628, PMID 22837038, PMID 23027880, PMID 23552330, PMID 23869824, PMID 24262162, PMID 24631802, PMID 24655729, PMID 25125777, PMID 26467901, PMID 26590659, PMID 26751635, PMID 26827074, PMID 27017543, PMID 27536708, PMID 28002679, PMID 28017241, PMID 28045953, PMID 28178885, PMID 28381130, PMID 28600189
2023 (6), 2014 (4), 2015 (4), 2018 (4), 2016 (2), 2017 (2), 2025 (2), 2005 (1), 2019 (1), R21HD108587 (1), U01NS082329 (1), UL1TR002538 (1), UM1AI109565 (1)